case_images: PMC5606108_01
case_images: PMC5606108_02
case_images: Plasma viral load and CD4 cell count follow-up from 2008 to 2016 in Case 1. Arrow indicates the time of switching to DTG/RPV dual therapy. X + 0 indicates the time of first administration of anti-retroviral drugs. Abbreviations: TDF/FTC, tenofovir/emtricitabine; ABC/3Tc, abacavir/lamivudine; RPV, rilpivirine; DRV/r, darunavir/ritonavir; MVC, maraviroc; RAL, raltegravir; DTG, dolutegravir
case_images: 40780_2017_93_Fig1_HTML.jpg
case_images: PMC5606108_02_40780_2017_93_Fig1_HTML.jpg
case_images: Fig1
case_images: At the last available follow-up (12 months after switching to DTG/RPV), HIV-1 viral load remained below the lower limit of quantification (< 40 copies/mL) and CD4 cell count was maintained at 474 cells/mL (Fig. 1).
case_images: PMC5606108_03
case_images: Plasma viral load and CD4 cell count follow-up from 2009 to 2016 in Case 2. Arrow indicates the time of switching to DTG/RPV dual therapy. X + 0 indicates the time of first administration of anti-retroviral drugs. Abbreviations: TDF/FTC, tenofovir/emtricitabine; ABC/3Tc, abacavir/lamivudine; RPV, rilpivirine; LPV/r, lopinavir/ritonavir; EFV, efavirenz; DTG, dolutegravir
case_images: 40780_2017_93_Fig2_HTML.jpg
case_images: PMC5606108_03_40780_2017_93_Fig2_HTML.jpg
case_images: Fig2